Close

BofA/Merrill Lynch Downgrades Intercept (ICPT) to Neutral on Lack of Catalysts

May 19, 2015 11:51 AM EDT
Get Alerts ICPT Hot Sheet
Price: $19.00 --0%

Rating Summary:
    13 Buy, 17 Hold, 3 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 13 | Down: 11 | New: 11
Join SI Premium – FREE

BofA/Merrill Lynch downgraded Intercept Pharmaceuticals (NASDAQ: ICPT) from Buy to Neutral with a price target of $315. Earlier Intercept announced plans for an international Phase 3 trial of OCA in NASH. Analyst Ying Haung sees the design "as expected" though the trial size is larger. The downgrade was tied to a lack of catalysts going forward.

For an analyst ratings summary and ratings history on Intercept Pharmaceuticals click here. For more ratings news on Intercept Pharmaceuticals click here.

Shares of Intercept Pharmaceuticals closed at $313.98 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Downgrades, Hot Comments, Hot Downgrades, Momentum Movers, Trader Talk